Background: A percent brain volume change (PBVC) cut-off of −0.4% per year has been proposed to distinguish between pathological and physiological changes in multiple sclerosis (MS). Unfortunately, standardized PBVC measurement is not always feasible on scans acquired outside research studies or academic centers. Percent lateral ventricular volume change (PLVVC) is a strong surrogate measure of PBVC, and may be more feasible for atrophy assessment on real-world scans. However, the PLVVC rate corresponding to the established PBVC cut-off of −0.4% is unknown. Objective: To establish a pathological PLVVC expansion rate cut-off analogous to −0.4% PBVC. Methods: We used three complementary approaches. First, the original follow-up-length-weighte...
PURPOSE: To investigate intercenter agreement of brain volume (change) measurement in multiple scle...
Objective To assess whether it is feasible to establish specific cut-off values able to discriminate...
OBJECTIVE: To assess the time course of brain atrophy and the difference across clinical subtypes in...
Background: Baseline brain volume (BV) is predictive at a group level but is difficult to interpret ...
Background: In multiple sclerosis (MS), brain atrophy depicted by magnetic resonance imaging reflect...
Background: Methodological challenges limit the use of brain atrophy and lesion burden measures in t...
Introduction: Multiple sclerosis (MS) is a common neurological disease causing intermittent or cumul...
Methodological challenges limit the use of brain atrophy and lesion burden measures in the follow-up...
Background: Volumetric MRI surrogate markers of disease progression are lacking. Objective: To estab...
Aim of this study was to investigate the reliability and validity of 2D linear measures of ventricul...
Objective: To define values of normalized brain volume (NBV) that can be categorized as low, medium,...
Linear measures of cerebral ventricular enlargement may act as surrogate measures of cerebral atroph...
Objective: To define values of normalized brain volume (NBV) that can be categorized as low, medium,...
PURPOSE: To investigate intercenter agreement of brain volume (change) measurement in multiple scle...
Objective To assess whether it is feasible to establish specific cut-off values able to discriminate...
OBJECTIVE: To assess the time course of brain atrophy and the difference across clinical subtypes in...
Background: Baseline brain volume (BV) is predictive at a group level but is difficult to interpret ...
Background: In multiple sclerosis (MS), brain atrophy depicted by magnetic resonance imaging reflect...
Background: Methodological challenges limit the use of brain atrophy and lesion burden measures in t...
Introduction: Multiple sclerosis (MS) is a common neurological disease causing intermittent or cumul...
Methodological challenges limit the use of brain atrophy and lesion burden measures in the follow-up...
Background: Volumetric MRI surrogate markers of disease progression are lacking. Objective: To estab...
Aim of this study was to investigate the reliability and validity of 2D linear measures of ventricul...
Objective: To define values of normalized brain volume (NBV) that can be categorized as low, medium,...
Linear measures of cerebral ventricular enlargement may act as surrogate measures of cerebral atroph...
Objective: To define values of normalized brain volume (NBV) that can be categorized as low, medium,...
PURPOSE: To investigate intercenter agreement of brain volume (change) measurement in multiple scle...
Objective To assess whether it is feasible to establish specific cut-off values able to discriminate...
OBJECTIVE: To assess the time course of brain atrophy and the difference across clinical subtypes in...